InsiderPulseNo transactions found.
| Metric | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Grant Revenue | $336K-45.5% | $617K+10.7% | $558K-43.6% | $989K |
| Research and development | $1.9M-7.5% | $2.1M+17.2% | $1.7M-26.8% | $2.4M |
| General and administrative | $3.7M+20.5% | $3.1M+81.2% | $1.7M-15.7% | $2.0M |
| Total Operating Expenses | $5.6M+9.3% | $5.1M+48.9% | $3.5M-21.7% | $4.4M |
| Total Operating Loss | -$5.3M-16.8% | -$4.5M-56.2% | -$2.9M+15.4% | -$3.4M |
| Research and development credit | $9K | — | — | — |
| Interest expense | -$210K+12.0% | -$239K-10.6% | -$216K-32.1% | -$164K |
| Total Other Income (Expense), Net | -$210K+8.4% | -$230K-14.6% | -$201K-58.2% | -$127K |
| Net Loss | -$5.5M-15.6% | -$4.8M-53.5% | -$3.1M+12.7% | -$3.6M |
| Net Loss attributable to noncontrolling interest | -$74K-151.0% | -$30K | — | — |
| Net Loss attributable to common stockholders | -$5.4M-14.8% | -$4.7M-52.6% | -$3.1M+12.7% | -$3.6M |
| Basic Loss Per Common Share | -$0.01+0.0% | -$0.01+0.0% | -$0.01+0.0% | -$0.01 |
| Diluted Loss Per Common Share | -$0.01+0.0% | -$0.01+0.0% | -$0.01+0.0% | -$0.01 |
| Weighted Average Number of Common Shares Outstanding - Basic | $420.3M+0.1% | $419.8M+0.1% | $419.5M+0.0% | $419.5M |
| Weighted Average Number of Common Shares Outstanding - Diluted | $420.3M+0.1% | $419.8M+0.1% | $419.5M+0.0% | $419.5M |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
Bascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus’s VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis
Provectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
Provectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment